130 related articles for article (PubMed ID: 9930307)
1. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model.
Xing X; Zhang S; Chang JY; Tucker SD; Chen H; Huang L; Hung MC
Gene Ther; 1998 Nov; 5(11):1538-44. PubMed ID: 9930307
[TBL] [Abstract][Full Text] [Related]
2. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC
Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737
[TBL] [Abstract][Full Text] [Related]
3. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
4. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
[TBL] [Abstract][Full Text] [Related]
5. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery.
Ueno NT; Xia W; Tucker SD; Zhang S; Lopez-Berestein G; Huang L; Hung MC
Oncol Rep; 1999; 6(2):257-62. PubMed ID: 10022986
[TBL] [Abstract][Full Text] [Related]
6. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.
Yoo GH; Hung MC; Lopez-Berestein G; LaFollette S; Ensley JF; Carey M; Batson E; Reynolds TC; Murray JL
Clin Cancer Res; 2001 May; 7(5):1237-45. PubMed ID: 11350889
[TBL] [Abstract][Full Text] [Related]
8. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
Zhang Y; Yu D; Xia W; Hung MC
Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
[TBL] [Abstract][Full Text] [Related]
10. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
11. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Ueno NT; Yu D; Hung MC
Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
Chang JY; Xia W; Shao R; Hung MC
Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
[TBL] [Abstract][Full Text] [Related]
15. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
Ueno NT; Bartholomeusz C; Xia W; Anklesaria P; Bruckheimer EM; Mebel E; Paul R; Li S; Yo GH; Huang L; Hung MC
Cancer Res; 2002 Nov; 62(22):6712-6. PubMed ID: 12438271
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
17. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.
Hortobagyi GN; Ueno NT; Xia W; Zhang S; Wolf JK; Putnam JB; Weiden PL; Willey JS; Carey M; Branham DL; Payne JY; Tucker SD; Bartholomeusz C; Kilbourn RG; De Jager RL; Sneige N; Katz RL; Anklesaria P; Ibrahim NK; Murray JL; Theriault RL; Valero V; Gershenson DM; Bevers MW; Huang L; Lopez-Berestein G; Hung MC
J Clin Oncol; 2001 Jul; 19(14):3422-33. PubMed ID: 11454891
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficiency and specificity of ovarian cancer gene therapy in rats with a novel nonviral gene delivery system (GE7) via intraovarian artery perfusion approach.
Jiang W; Xu CJ; Shao ZM; Zhou WJ; Ye B; Tian PK; Zhu JD; Gu JR
Cancer Gene Ther; 2005 Oct; 12(10):810-7. PubMed ID: 15905861
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model.
Lee MJ; Cho SS; You JR; Lee Y; Kang BD; Choi JS; Park JW; Suh YL; Kim JA; Kim DK; Park JS
Gene Ther; 2002 Jul; 9(13):859-66. PubMed ID: 12080380
[TBL] [Abstract][Full Text] [Related]
20. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
